Super-antibodies that can bind to targets within cells, rather than on their surface, could lead to a new range of treatments for diseases, a biotech company claims. “Most good targets for diseases are inside cells,” says Charles Morgan, president of InNexus Biotechnology of Vancouver, Canada, which has developed the super-antibody technology. Super-antibodies could be used to target bacteria and viruses (including HIV) inside cells, for instance, or abnormal proteins that turn cells cancerous. In theory, they could do everything that the small molecules of most conventional drugs do, and more.
